- Innovation Insights
- Business Professionals
- IP Strategists
- IP Practitioners
- Products & Services
- About PatentSight
Over the last decades the world has seen a range of commercially successful products. Especially in the pharma sector blockbuster drugs yield exceedingly high revenues. The main reason for the commercial success of these products is the fact that the underlying active ingredient was and still is protected by patents. Hence, the drug can be sold exclusively. After these patents reach their 20 year maximum lifetime, usually, cheaper generics enter the market drastically decreasing revenue for the original drug. To tackle the effects of such patent cliffs companies try to extend the patent protection of their blockbuster technology. In this webinar, we will have a look at the most common strategies and how to spot them.
Kae Gruner provides counsel to Acella Pharmaceuticals and its affiliates on intellectual property, pharmaceutical manufacturing, marketing, & distribution, regulatory matters, and commercial contracts. She earned her bachelor’s degree in Biology from Hiram College in Ohio, graduating with honors and joining Phi Beta Kappa. She then graduated from the University of Akron School of Law with her Juris Doctor and LL.M. in intellectual property. Before joining Acella, Kae worked as Associate Patent Attorney with Pearne & Gordon LLP in Cleveland and as IP Licensing Associate in the Office of Technology Transfer at Emory University in Atlanta.
Dr. Sarbani Chattopadhyay PhD, LL.M., is a computational biologist with a PhD in Biochemistry from the University of Calcutta in Calcutta, India, and a LL.M. in European IP and IT Law from the University of Göttingen in Göttingen, Germany. As a Consultant at LexisNexis PatentSight GmbH, in Germany, she works with clients all across the globe in different technology fields, specializing in searching and analyzing patents, patent landscape and technologies from patent perspective.
Gene is the founder of IPWatchdog.com, a patent attorney, law professor, and leading commentator on patent law and innovation policy. Gene has been named one of the world’s leading IP Strategists by IAM Magazine.